Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

A major drawback in the clinical use of the oral anticoagulants that directly inhibit factor Xa in order to prevent blood clot formation is the potential for life threatening bleeding events. Here the authors describe factor Xa variants that are refractory to inhibition by these anticoagulants and c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Daniël Verhoef, Koen M. Visscher, C. Ruben Vosmeer, Ka Lei Cheung, Pieter H. Reitsma, Daan P. Geerke, Mettine H. A. Bos
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/b141be2853c5434db46bb976a6a0ac12
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b141be2853c5434db46bb976a6a0ac12
record_format	dspace
spelling	oai:doaj.org-article:b141be2853c5434db46bb976a6a0ac122021-12-02T14:41:08ZEngineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors10.1038/s41467-017-00647-92041-1723https://doaj.org/article/b141be2853c5434db46bb976a6a0ac122017-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-017-00647-9https://doaj.org/toc/2041-1723A major drawback in the clinical use of the oral anticoagulants that directly inhibit factor Xa in order to prevent blood clot formation is the potential for life threatening bleeding events. Here the authors describe factor Xa variants that are refractory to inhibition by these anticoagulants and could serve as rescue agents in treated patients.Daniël VerhoefKoen M. VisscherC. Ruben VosmeerKa Lei CheungPieter H. ReitsmaDaan P. GeerkeMettine H. A. BosNature PortfolioarticleScienceQENNature Communications, Vol 8, Iss 1, Pp 1-10 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Daniël Verhoef Koen M. Visscher C. Ruben Vosmeer Ka Lei Cheung Pieter H. Reitsma Daan P. Geerke Mettine H. A. Bos Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
description	A major drawback in the clinical use of the oral anticoagulants that directly inhibit factor Xa in order to prevent blood clot formation is the potential for life threatening bleeding events. Here the authors describe factor Xa variants that are refractory to inhibition by these anticoagulants and could serve as rescue agents in treated patients.
format	article
author	Daniël Verhoef Koen M. Visscher C. Ruben Vosmeer Ka Lei Cheung Pieter H. Reitsma Daan P. Geerke Mettine H. A. Bos
author_facet	Daniël Verhoef Koen M. Visscher C. Ruben Vosmeer Ka Lei Cheung Pieter H. Reitsma Daan P. Geerke Mettine H. A. Bos
author_sort	Daniël Verhoef
title	Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
title_short	Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
title_full	Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
title_fullStr	Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
title_full_unstemmed	Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
title_sort	engineered factor xa variants retain procoagulant activity independent of direct factor xa inhibitors
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/b141be2853c5434db46bb976a6a0ac12
work_keys_str_mv	AT danielverhoef engineeredfactorxavariantsretainprocoagulantactivityindependentofdirectfactorxainhibitors AT koenmvisscher engineeredfactorxavariantsretainprocoagulantactivityindependentofdirectfactorxainhibitors AT crubenvosmeer engineeredfactorxavariantsretainprocoagulantactivityindependentofdirectfactorxainhibitors AT kaleicheung engineeredfactorxavariantsretainprocoagulantactivityindependentofdirectfactorxainhibitors AT pieterhreitsma engineeredfactorxavariantsretainprocoagulantactivityindependentofdirectfactorxainhibitors AT daanpgeerke engineeredfactorxavariantsretainprocoagulantactivityindependentofdirectfactorxainhibitors AT mettinehabos engineeredfactorxavariantsretainprocoagulantactivityindependentofdirectfactorxainhibitors
_version_	1718390013828268032

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

Ejemplares similares